{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T22:40:27Z","timestamp":1792449627658,"version":"4.5.0"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T00:00:00Z","timestamp":1792368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T00:00:00Z","timestamp":1792368000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Innere Medizin"],"DOI":"10.1007\/s00108-026-02171-9","type":"journal-article","created":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T09:29:41Z","timestamp":1792402181000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Therapie des Diabetes mellitus Typ\u00a02","Treatment of type\u00a02 diabetes mellitus"],"prefix":"10.1007","author":[{"given":"Reiner","family":"Jumpertz von Schwartzenberg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Kir\u00e1ly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,19]]},"reference":[{"key":"2171_CR1","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/S2213-8587(18)30051-2","volume":"6","author":"E Ahlqvist","year":"2018","unstructured":"Ahlqvist\u00a0E, Storm\u00a0P, K\u00e4r\u00e4j\u00e4m\u00e4ki\u00a0A et\u00a0al (2018) Novel subgroups of adult-onset diabetes and their association with outcomes: a data-driven cluster analysis of six variables. Lancet Diabetes Endocrinol 6:361\u2013369. https:\/\/doi.org\/10.1016\/S2213-8587(18)30051-2","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2171_CR2","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1016\/S2213-8587(19)30187-1","volume":"7","author":"OP Zaharia","year":"2019","unstructured":"Zaharia\u00a0OP, Strassburger\u00a0K, Strom\u00a0A et\u00a0al (2019) Risk of diabetes-associated diseases in subgroups of patients with recent-onset diabetes: a 5\u2011year follow-up study. Lancet Diabetes Endocrinol 7:684\u2013694. https:\/\/doi.org\/10.1016\/S2213-8587(19)30187-1","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2171_CR3","unstructured":"Koliaki C (2022) The evolving concept of diabetes-related subgroups: from a\u00a0one-size-fits-all approach to precision medicine. 65(11):1839\u20131851"},{"key":"2171_CR4","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1146\/annurev-immunol-031210-101322","volume":"29","author":"MF Gregor","year":"2011","unstructured":"Gregor\u00a0MF, Hotamisligil\u00a0GS (2011) Inflammatory Mechanisms in Obesity. Annu Rev Immunol 29:415\u2013445. https:\/\/doi.org\/10.1146\/annurev-immunol-031210-101322","journal-title":"Annu Rev Immunol"},{"key":"2171_CR5","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1038\/s41591-020-1116-9","volume":"27","author":"R Wagner","year":"2021","unstructured":"Wagner\u00a0R, Heni\u00a0M, Tab\u00e1k\u00a0AG et\u00a0al (2021) Pathophysiology-based subphenotyping of individuals at elevated risk for type 2 diabetes. Nat Med 27:49\u201357. https:\/\/doi.org\/10.1038\/s41591-020-1116-9","journal-title":"Nat Med"},{"key":"2171_CR6","doi-asserted-by":"publisher","first-page":"773","DOI":"10.2337\/db09-9028","volume":"58","author":"RA DeFronzo","year":"2009","unstructured":"DeFronzo\u00a0RA (2009) From the Triumvirate to the Ominous Octet: A New Paradigm for the Treatment of Type 2 Diabetes Mellitus. Diabetes 58:773\u2013795. https:\/\/doi.org\/10.2337\/db09-9028","journal-title":"Diabetes"},{"key":"2171_CR7","doi-asserted-by":"publisher","first-page":"2753","DOI":"10.2337\/dci22-0034","volume":"45","author":"MJ Davies","year":"2022","unstructured":"Davies\u00a0MJ, Aroda\u00a0VR, Collins\u00a0BS et\u00a0al (2022) Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 45:2753\u20132786. https:\/\/doi.org\/10.2337\/dci22-0034","journal-title":"Diabetes Care"},{"key":"2171_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2019.107946","volume":"159","author":"G Schernthaner","year":"2020","unstructured":"Schernthaner\u00a0G, Schernthaner\u00a0GH (2020) The right place for metformin today. Diabetes Res Clin Pract Suppl 159:107946. https:\/\/doi.org\/10.1016\/j.diabres.2019.107946","journal-title":"Diabetes Res Clin Pract"},{"key":"2171_CR9","doi-asserted-by":"publisher","unstructured":"(2022) Impact of diabetes on the effects of sodium glucose co-transporter\u20112 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials. Lancet Lond Engl 400:1788\u20131801. https:\/\/doi.org\/10.1016\/S0140-6736(22)02074-8","DOI":"10.1016\/S0140-6736(22)02074-8"},{"key":"2171_CR10","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","volume":"375","author":"SP Marso","year":"2016","unstructured":"Marso\u00a0SP, Bain\u00a0SC, Consoli\u00a0A et\u00a0al (2016) Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med 375:1834\u20131844. https:\/\/doi.org\/10.1056\/NEJMoa1607141","journal-title":"N Engl J Med"},{"key":"2171_CR11","doi-asserted-by":"publisher","first-page":"1754","DOI":"10.1210\/jc.2015-3754","volume":"101","author":"VR Aroda","year":"2016","unstructured":"Aroda\u00a0VR, Edelstein\u00a0SL, Goldberg\u00a0RB et\u00a0al (2016) Long-term Metformin Use and Vitamin B12 Deficiency in the Diabetes Prevention Program Outcomes Study. J\u00a0Clin Endocrinol Metab 101:1754\u20131761. https:\/\/doi.org\/10.1210\/jc.2015-3754","journal-title":"J Clin Endocrinol Metab"},{"key":"2171_CR12","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","volume":"383","author":"HJL Heerspink","year":"2020","unstructured":"Heerspink\u00a0HJL, Stef\u00e1nsson\u00a0BV, Correa-Rotter\u00a0R et\u00a0al (2020) Dapagliflozin in Patients with Chronic Kidney Disease. N Engl J Med 383:1436\u20131446. https:\/\/doi.org\/10.1056\/NEJMoa2024816","journal-title":"N Engl J Med"},{"key":"2171_CR13","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1038\/s41581-024-00836-y","volume":"20","author":"DV O\u2019Hara","year":"2024","unstructured":"O\u2019Hara\u00a0DV, Lam\u00a0CSP, McMurray\u00a0JJV et\u00a0al (2024) Applications of SGLT2 inhibitors beyond glycaemic control. Nat Rev Nephrol 20:513\u2013529. https:\/\/doi.org\/10.1038\/s41581-024-00836-y","journal-title":"Nat Rev Nephrol"},{"key":"2171_CR14","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1038\/s41581-020-00350-x","volume":"17","author":"A Marton","year":"2021","unstructured":"Marton\u00a0A, Kaneko\u00a0T, Kovalik\u00a0JP et\u00a0al (2021) Organ protection by SGLT2 inhibitors: role of metabolic energy and water conservation. Nat Rev Nephrol 17:65\u201377. https:\/\/doi.org\/10.1038\/s41581-020-00350-x","journal-title":"Nat Rev Nephrol"},{"key":"2171_CR15","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/S2213-8587(23)00385-6","volume":"12","author":"ME Lean","year":"2024","unstructured":"Lean\u00a0ME, Leslie\u00a0WS, Barnes\u00a0AC et\u00a0al (2024) 5\u2011year follow-up of the randomised Diabetes Remission Clinical Trial (DiRECT) of continued support for weight loss maintenance in the UK: an extension study. Lancet Diabetes Endocrinol 12:233\u2013246. https:\/\/doi.org\/10.1016\/S2213-8587(23)00385-6","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2171_CR16","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1038\/s41591-025-04102-x","volume":"32","author":"N Kr\u00fcger","year":"2026","unstructured":"Kr\u00fcger\u00a0N, Schneeweiss\u00a0S, Desai\u00a0RJ et\u00a0al (2026) Cardiovascular outcomes of semaglutide and tirzepatide for patients with type 2 diabetes in clinical practice. Nat Med 32:342\u2013352. https:\/\/doi.org\/10.1038\/s41591-025-04102-x","journal-title":"Nat Med"},{"key":"2171_CR17","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1056\/NEJMoa2107519","volume":"385","author":"JP Fr\u00edas","year":"2021","unstructured":"Fr\u00edas\u00a0JP, Davies\u00a0MJ, Rosenstock\u00a0J et\u00a0al (2021) Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. N Engl J Med 385:503\u2013515. https:\/\/doi.org\/10.1056\/NEJMoa2107519","journal-title":"N Engl J Med"},{"key":"2171_CR18","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1016\/S0140-6736(25)02105-1","volume":"407","author":"MA Nauck","year":"2026","unstructured":"Nauck\u00a0MA, Tuttle\u00a0KR, Tsch\u00f6p\u00a0MH, Bl\u00fcher\u00a0M (2026) Glucagon-like receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits. Lancet 407:892\u2013908. https:\/\/doi.org\/10.1016\/S0140-6736(25)02105-1","journal-title":"Lancet"},{"key":"2171_CR19","doi-asserted-by":"publisher","DOI":"10.1111\/obr.13543","volume":"24","author":"OS Alkhezi","year":"2023","unstructured":"Alkhezi\u00a0OS, Alahmed\u00a0AA, Alfayez\u00a0OM et\u00a0al (2023) Comparative effectiveness of glucagon-like peptide\u20111 receptor agonists for the management of obesity in adults without diabetes: A network meta-analysis of randomized clinical trials. Obes Rev 24:e13543. https:\/\/doi.org\/10.1111\/obr.13543","journal-title":"Obes Rev Off J Int Assoc Study Obes"},{"key":"2171_CR20","doi-asserted-by":"publisher","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","volume":"389","author":"AM Lincoff","year":"2023","unstructured":"Lincoff\u00a0AM, Brown-Frandsen\u00a0K, Colhoun\u00a0HM et\u00a0al (2023) Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med 389:2221\u20132232. https:\/\/doi.org\/10.1056\/NEJMoa2307563","journal-title":"N Engl J Med"},{"key":"2171_CR21","unstructured":"Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type\u00a02 Diabetes | NEJM. N Engl J Med"},{"key":"2171_CR22","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-024-02319-7","volume":"23","author":"F Taktaz","year":"2024","unstructured":"Taktaz\u00a0F, Fontanella\u00a0RA, Scisciola\u00a0L et\u00a0al (2024) Bridging the gap between GLP1-receptor agonists and cardiovascular outcomes: evidence for the role of tirzepatide. Cardiovasc Diabetol 23:242. https:\/\/doi.org\/10.1186\/s12933-024-02319-7","journal-title":"Cardiovasc Diabetol"},{"key":"2171_CR23","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1111\/dom.12926","volume":"19","author":"M Monami","year":"2017","unstructured":"Monami\u00a0M, Nreu\u00a0B, Scatena\u00a0A et\u00a0al (2017) Safety issues with glucagon-like peptide\u20111 receptor agonists (pancreatitis, pancreatic cancer and cholelithiasis): Data from randomized controlled trials. Diabetes Obes Metab 19:1233\u20131241. https:\/\/doi.org\/10.1111\/dom.12926","journal-title":"Diabetes Obes Metab"},{"key":"2171_CR24","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1089\/thy.2023.0530","volume":"34","author":"AE Espinosa De Ycaza","year":"2024","unstructured":"Espinosa De Ycaza\u00a0AE, Brito\u00a0JP, McCoy\u00a0RG et\u00a0al (2024) Glucagon-Like Peptide\u20111 Receptor Agonists and Thyroid Cancer: A Narrative Review. Thyroid\u00ae 34:403\u2013418. https:\/\/doi.org\/10.1089\/thy.2023.0530","journal-title":"Thyroid\u00ae"},{"key":"2171_CR25","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1001\/jamapsychiatry.2025.0091","volume":"82","author":"P Ebrahimi","year":"2025","unstructured":"Ebrahimi\u00a0P, Batlle\u00a0JC, Ayati\u00a0A et\u00a0al (2025) Suicide and Self-Harm Events With GLP\u20111 Receptor Agonists in Adults With Diabetes or Obesity: A Systematic Review and Meta-Analysis. JAMA Psychiatry 82:888\u2013895. https:\/\/doi.org\/10.1001\/jamapsychiatry.2025.0091","journal-title":"JAMA Psychiatry"},{"key":"2171_CR26","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1001\/jamaophthalmol.2024.2296","volume":"142","author":"JT Hathaway","year":"2024","unstructured":"Hathaway\u00a0JT, Shah\u00a0MP, Hathaway\u00a0DB et\u00a0al (2024) Risk of Nonarteritic Anterior Ischemic Optic Neuropathy in Patients Prescribed Semaglutide. JAMA Ophthalmol 142:732\u2013739. https:\/\/doi.org\/10.1001\/jamaophthalmol.2024.2296","journal-title":"JAMA Ophthalmol"},{"key":"2171_CR27","doi-asserted-by":"publisher","DOI":"10.3390\/jcm15062358","volume":"15","author":"G Cassataro","year":"2026","unstructured":"Cassataro\u00a0G, Geraci\u00a0G, Giusti\u00a0MA et\u00a0al (2026) The Cardiovascular Burden of Diabetes: Risk Factors, Clinical Phenotypes, and Personalized Cardiometabolic Management. J\u00a0Clin Med 15:2358. https:\/\/doi.org\/10.3390\/jcm15062358","journal-title":"J Clin Med"},{"key":"2171_CR28","doi-asserted-by":"publisher","first-page":"2022","DOI":"10.1161\/CIRCULATIONAHA.118.038868","volume":"139","author":"TA Zelniker","year":"2019","unstructured":"Zelniker\u00a0TA, Wiviott\u00a0SD, Raz\u00a0I et\u00a0al (2019) Comparison of the Effects of Glucagon-Like Peptide Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors for Prevention of Major Adverse Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus. Circulation 139:2022\u20132031. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.118.038868","journal-title":"Circulation"},{"key":"2171_CR29","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.ejim.2021.11.008","volume":"96","author":"R G\u00f3mez-Huelgas","year":"2022","unstructured":"G\u00f3mez-Huelgas\u00a0R, Sanz-C\u00e1novas\u00a0J, Cobos-Palacios\u00a0L et\u00a0al (2022) Glucagon-like peptide\u20111 receptor agonists and sodium-glucose cotransporter 2 inhibitors for cardiovascular and renal protection: A treatment approach far beyond their glucose-lowering effect. Eur J Intern Med 96:26\u201333. https:\/\/doi.org\/10.1016\/j.ejim.2021.11.008","journal-title":"Eur J Intern Med"},{"key":"2171_CR30","doi-asserted-by":"crossref","unstructured":"(2026) Effect of Hyperketonemia on Myocardial Function in Patients With Heart Failure and Type 2 Diabetes | Diabetes | American Diabetes Association. Diabetes 74(1):43","DOI":"10.2337\/db24-0406"},{"key":"2171_CR31","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/S2213-8587(25)00295-5","volume":"14","author":"E Vazquez Arreola","year":"2026","unstructured":"Vazquez Arreola\u00a0E, Gong\u00a0Q, Hanson\u00a0RL et\u00a0al (2026) Prediabetes remission and cardiovascular morbidity and mortality: post-hoc analyses from the Diabetes Prevention Program Outcome study and the DaQing Diabetes Prevention Outcome study. Lancet Diabetes Endocrinol 14:137\u2013148. https:\/\/doi.org\/10.1016\/S2213-8587(25)00295-5","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2171_CR32","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","volume":"383","author":"GL Bakris","year":"2020","unstructured":"Bakris\u00a0GL, Agarwal\u00a0R, Anker\u00a0SD et\u00a0al (2020) Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes. N Engl J Med 383:2219\u20132229. https:\/\/doi.org\/10.1056\/NEJMoa2025845","journal-title":"N Engl J Med"},{"key":"2171_CR33","doi-asserted-by":"publisher","first-page":"2252","DOI":"10.1056\/NEJMoa2110956","volume":"385","author":"B Pitt","year":"2021","unstructured":"Pitt\u00a0B, Filippatos\u00a0G, Agarwal\u00a0R et\u00a0al (2021) Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes. N Engl J Med 385:2252\u20132263. https:\/\/doi.org\/10.1056\/NEJMoa2110956","journal-title":"N Engl J Med"},{"key":"2171_CR34","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1056\/NEJMoa2401943","volume":"391","author":"R Loomba","year":"2024","unstructured":"Loomba\u00a0R, Hartman\u00a0ML, Lawitz\u00a0EJ et\u00a0al (2024) Tirzepatide for Metabolic Dysfunction-Associated Steatohepatitis with Liver Fibrosis. N Engl J Med 391:299\u2013310. https:\/\/doi.org\/10.1056\/NEJMoa2401943","journal-title":"N Engl J Med"},{"key":"2171_CR35","doi-asserted-by":"publisher","first-page":"S368","DOI":"10.2337\/diabetes.51.2007.S368","volume":"51","author":"P Proks","year":"2002","unstructured":"Proks\u00a0P, Reimann\u00a0F, Green\u00a0N et\u00a0al (2002) Sulfonylurea Stimulation of Insulin Secretion. Diabetes 51:S368\u2013S376. https:\/\/doi.org\/10.2337\/diabetes.51.2007.S368","journal-title":"Diabetes"},{"key":"2171_CR36","doi-asserted-by":"publisher","first-page":"305","DOI":"10.7326\/M15-1774","volume":"165","author":"K Cusi","year":"2016","unstructured":"Cusi\u00a0K, Orsak\u00a0B, Bril\u00a0F et\u00a0al (2016) Long-Term Pioglitazone Treatment for Patients With Nonalcoholic Steatohepatitis and Prediabetes or Type 2 Diabetes Mellitus. Ann Intern Med 165:305\u2013315. https:\/\/doi.org\/10.7326\/M15-1774","journal-title":"Ann Intern Med"},{"key":"2171_CR37","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1055\/a-1242-9809","volume":"130","author":"A Fritsche","year":"2022","unstructured":"Fritsche\u00a0A, Heni\u00a0M, Peter\u00a0A et\u00a0al (2022) Considering Insulin Secretory Capacity as Measured by a Fasting C\u2011Peptide\/Glucose Ratio in Selecting Glucose-Lowering Medications. Exp Clin Endocrinol Diabetes Off J Ger Soc Endocrinol Ger Diabetes Assoc 130:200\u2013204. https:\/\/doi.org\/10.1055\/a-1242-9809","journal-title":"Exp Clin Endocrinol Diabetes Off J Ger Soc Endocrinol Ger Diabetes Assoc"},{"key":"2171_CR38","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1056\/NEJMoa2303208","volume":"389","author":"J Rosenstock","year":"2023","unstructured":"Rosenstock\u00a0J, Bain\u00a0SC, Gowda\u00a0A et\u00a0al (2023) Weekly Icodec versus Daily Glargine U100 in Type 2 Diabetes without Previous Insulin. N Engl J Med 389:297\u2013308. https:\/\/doi.org\/10.1056\/NEJMoa2303208","journal-title":"N Engl J Med"},{"key":"2171_CR39","doi-asserted-by":"publisher","first-page":"4043","DOI":"10.1093\/eurheartj\/ehad192","volume":"44","author":"N Marx","year":"2023","unstructured":"Marx\u00a0N, Federici\u00a0M, Sch\u00fctt\u00a0K et\u00a0al (2023) 2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes: Developed by the task force on the management of cardiovascular disease in patients with diabetes of the European Society of Cardiology (ESC). Eur Heart J Qual Care Clin Outcomes 44:4043\u20134140. https:\/\/doi.org\/10.1093\/eurheartj\/ehad192","journal-title":"Eur Heart J"},{"key":"2171_CR40","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/S0140-6736(20)32649-0","volume":"397","author":"G Mingrone","year":"2021","unstructured":"Mingrone\u00a0G, Panunzi\u00a0S, De Gaetano\u00a0A et\u00a0al (2021) Metabolic surgery versus conventional medical therapy in patients with type 2 diabetes: 10-year follow-up of an open-label, single-centre, randomised controlled trial. Lancet 397:293\u2013304. https:\/\/doi.org\/10.1016\/S0140-6736(20)32649-0","journal-title":"Lancet"},{"key":"2171_CR41","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1111\/joim.12012","volume":"273","author":"L Sj\u00f6str\u00f6m","year":"2013","unstructured":"Sj\u00f6str\u00f6m\u00a0L (2013) Review of the key results from the Swedish Obese Subjects (SOS) trial \u2013 a prospective controlled intervention study of bariatric surgery. J\u00a0Intern Med 273:219\u2013234. https:\/\/doi.org\/10.1111\/joim.12012","journal-title":"J Intern Med"},{"key":"2171_CR42","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/S2213-8587(18)30154-2","volume":"7","author":"N Stefan","year":"2019","unstructured":"Stefan\u00a0N, H\u00e4ring\u00a0HU, Cusi\u00a0K (2019) Non-alcoholic fatty liver disease: causes, diagnosis, cardiometabolic consequences, and treatment strategies. Lancet Diabetes Endocrinol 7:313\u2013324. https:\/\/doi.org\/10.1016\/S2213-8587(18)30154-2","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2171_CR43","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1056\/NEJMoa2401943","volume":"391","author":"R Loomba","year":"2024","unstructured":"Loomba\u00a0R, Hartman\u00a0ML, Lawitz\u00a0EJ et\u00a0al (2024) Tirzepatide for Metabolic Dysfunction\u2013Associated Steatohepatitis with Liver Fibrosis. N Engl J Med 391:299\u2013310. https:\/\/doi.org\/10.1056\/NEJMoa2401943","journal-title":"N Engl J Med"},{"key":"2171_CR44","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1056\/NEJMoa2309000","volume":"390","author":"SA Harrison","year":"2024","unstructured":"Harrison\u00a0SA, Bedossa\u00a0P, Guy\u00a0CD et\u00a0al (2024) A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis. N Engl J Med 390:497\u2013509. https:\/\/doi.org\/10.1056\/NEJMoa2309000","journal-title":"N Engl J Med"},{"key":"2171_CR45","doi-asserted-by":"publisher","first-page":"1593","DOI":"10.2337\/dci19-0028","volume":"42","author":"T Battelino","year":"2019","unstructured":"Battelino\u00a0T, Danne\u00a0T, Bergenstal\u00a0RM et\u00a0al (2019) Clinical Targets for Continuous Glucose Monitoring Data Interpretation: Recommendations From the International Consensus on Time in Range. Diabetes Care 42:1593\u20131603. https:\/\/doi.org\/10.2337\/dci19-0028","journal-title":"Diabetes Care"},{"key":"2171_CR46","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/S2213-8587(22)00319-9","volume":"11","author":"T Battelino","year":"2023","unstructured":"Battelino\u00a0T, Alexander\u00a0CM, Amiel\u00a0SA et\u00a0al (2023) Continuous glucose monitoring and metrics for clinical trials: an international consensus statement. Lancet Diabetes Endocrinol 11:42\u201357. https:\/\/doi.org\/10.1016\/S2213-8587(22)00319-9","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2171_CR47","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1056\/NEJMoa012512","volume":"346","author":"WC Knowler","year":"2002","unstructured":"Knowler\u00a0WC, Barrett-Connor\u00a0E, Fowler\u00a0SE et\u00a0al (2002) Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 346:393\u2013403. https:\/\/doi.org\/10.1056\/NEJMoa012512","journal-title":"N Engl J Med"},{"key":"2171_CR48","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1016\/S2213-8587(23)00235-8","volume":"11","author":"A Sandforth","year":"2023","unstructured":"Sandforth\u00a0A, von Schwartzenberg\u00a0RJ, Arreola\u00a0EV et\u00a0al (2023) Mechanisms of weight loss-induced remission in people with prediabetes: a post-hoc analysis of the randomised, controlled, multicentre Prediabetes Lifestyle Intervention Study (PLIS). Lancet Diabetes Endocrinol 11:798\u2013810. https:\/\/doi.org\/10.1016\/S2213-8587(23)00235-8","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2171_CR49","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1038\/s41591-020-1116-9","volume":"27","author":"R Wagner","year":"2021","unstructured":"Wagner\u00a0R, Heni\u00a0M, Tab\u00e1k\u00a0AG et\u00a0al (2021) Pathophysiology-based subphenotyping of individuals at elevated risk for type 2 diabetes. Nat Med 27:49\u201357. https:\/\/doi.org\/10.1038\/s41591-020-1116-9","journal-title":"Nat Med"},{"key":"2171_CR50","doi-asserted-by":"publisher","first-page":"3330","DOI":"10.1038\/s41591-025-03944-9","volume":"31","author":"A Sandforth","year":"2025","unstructured":"Sandforth\u00a0A, Arreola\u00a0EV, Hanson\u00a0RL et\u00a0al (2025) Prevention of type 2 diabetes through prediabetes remission without weight loss. Nat Med 31:3330\u20133340. https:\/\/doi.org\/10.1038\/s41591-025-03944-9","journal-title":"Nat Med"},{"key":"2171_CR51","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.m2297","volume":"370","author":"X Cai","year":"2020","unstructured":"Cai\u00a0X, Zhang\u00a0Y, Li\u00a0M et\u00a0al (2020) Association between prediabetes and risk of all cause mortality and cardiovascular disease: updated meta-analysis. Can J Hosp Pharm 370:m2297. https:\/\/doi.org\/10.1136\/bmj.m2297","journal-title":"The BMJ"},{"key":"2171_CR52","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.2337\/dc19-0244","volume":"42","author":"L Perreault","year":"2019","unstructured":"Perreault\u00a0L, Pan\u00a0Q, Schroeder\u00a0EB et\u00a0al (2019) Regression From Prediabetes to Normal Glucose Regulation and Prevalence of Microvascular Disease in the Diabetes Prevention Program Outcomes Study (DPPOS). Diabetes Care 42:1809\u20131815. https:\/\/doi.org\/10.2337\/dc19-0244","journal-title":"Diabetes Care"},{"key":"2171_CR53","doi-asserted-by":"publisher","first-page":"2438","DOI":"10.2337\/dci21-0034","volume":"44","author":"MC Riddle","year":"2021","unstructured":"Riddle\u00a0MC, Cefalu\u00a0WT, Evans\u00a0PH et\u00a0al (2021) Consensus Report: Definition and Interpretation of Remission in Type 2 Diabetes. Diabetes Care 44:2438\u20132444. https:\/\/doi.org\/10.2337\/dci21-0034","journal-title":"Diabetes Care"},{"key":"2171_CR54","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1016\/S0140-6736(17)33102-1","volume":"391","author":"ME Lean","year":"2018","unstructured":"Lean\u00a0ME, Leslie\u00a0WS, Barnes\u00a0AC et\u00a0al (2018) Primary care-led weight management for remission of type 2 diabetes (DiRECT): an open-label, cluster-randomised trial. The Lancet 391:541\u2013551. https:\/\/doi.org\/10.1016\/S0140-6736(17)33102-1","journal-title":"The Lancet"},{"key":"2171_CR55","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1056\/NEJMoa2410819","volume":"392","author":"AM Jastreboff","year":"2025","unstructured":"Jastreboff\u00a0AM, le Roux\u00a0CW, Stefanski\u00a0A et\u00a0al (2025) Tirzepatide for Obesity Treatment and Diabetes Prevention. N Engl J Med 392:958\u2013971. https:\/\/doi.org\/10.1056\/NEJMoa2410819","journal-title":"N Engl J Med"},{"key":"2171_CR56","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1056\/NEJMoa2301972","volume":"389","author":"AM Jastreboff","year":"2023","unstructured":"Jastreboff\u00a0AM, Kaplan\u00a0LM, Fr\u00edas\u00a0JP et\u00a0al (2023) Triple\u2013Hormone-Receptor Agonist Retatrutide for Obesity \u2014 A Phase 2 Trial. N Engl J Med 389:514\u2013526. https:\/\/doi.org\/10.1056\/NEJMoa2301972","journal-title":"N Engl J Med"},{"key":"2171_CR57","doi-asserted-by":"crossref","unstructured":"M\u00fcller TD, Bl\u00fcher M, Tsch\u00f6p MH, DiMarchi RD (2022) Anti-obesity drug discovery: advances and challenges. Nat Rev Drug Discov 21:201\u2013223. https:\/\/doi.org\/10.1038\/s41573-021-00337\u20118","DOI":"10.1038\/s41573-021-00337-8"},{"key":"2171_CR58","doi-asserted-by":"publisher","unstructured":"https:\/\/doi.org\/10.1056\/NEJMoa2505928","DOI":"10.1056\/NEJMoa2505928"},{"key":"2171_CR59","doi-asserted-by":"publisher","unstructured":"https:\/\/doi.org\/10.1056\/NEJMoa2206038","DOI":"10.1056\/NEJMoa2206038"}],"container-title":["Die Innere Medizin"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-026-02171-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00108-026-02171-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-026-02171-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T22:01:33Z","timestamp":1792447293000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00108-026-02171-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,19]]},"references-count":59,"alternative-id":["2171"],"URL":"https:\/\/doi.org\/10.1007\/s00108-026-02171-9","relation":{},"ISSN":["2731-7080","2731-7099"],"issn-type":[{"value":"2731-7080","type":"print"},{"value":"2731-7099","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,19]]},"assertion":[{"value":"16 July 2026","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 October 2026","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Gem\u00e4\u00df den Richtlinien des Springer Medizin Verlags werden Autorinnen und Autoren sowie die Wissenschaftliche Leitung im Rahmen der Manuskripterstellung und Manuskriptfreigabe aufgefordert, eine vollst\u00e4ndige Erkl\u00e4rung zu ihren finanziellen und nichtfinanziellen Interessen abzugeben.","order":1,"name":"Ethics","label":"Interessenkonflikt","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"R. Jumpertz von Schwartzenberg\n                      : A.\u00a0Finanzielle Interessen: Charit\u00e9 Symposium Diabetes und Adipositas \u2013\u00a0praxisrelevante Einblicke (gef\u00f6rdert durch: Sanofi, Amgen, Novo Nordisk, Lilly).\u00a0\u2013 B. Nichtfinanzielle Interessen: Niedergelassen, Zentrum f\u00fcr Endokrinologie und Stoffwechsel T\u00fcbingen (seit 01.04.2026); Universit\u00e4tsprofessor W3 Universit\u00e4tsklinikum T\u00fcbingen (bis 30.06.2026); Leitung Klinisches Studienzentrum, Klinik f\u00fcr Diabetologie, Endokrinologie und Nephrologie, Institut f\u00fcr Diabetesforschung und Metabolische Erkrankungen, Helmholtz Zentrum M\u00fcnchen (bis 30.06.2026).\n                      J. Kir\u00e1ly\n                      : A.\u00a0Finanzielle Interessen: Kostenerstattung: Boehringer Ingelheim: Kongress der Deutschen Diabetes Gesellschaft (DDG) 2024 \u2013\u00a0Hotelkosten, Teilnehmergeb\u00fchr (\u00fcber Kostenstelle des Universit\u00e4tsklinikums T\u00fcbingen); Ascendis Pharma: 69. Kongress f\u00fcr Endokrinologie (2026) - Hotelkosten, Teilnehmergeb\u00fchr.\u00a0\u2013 B. Nichtfinanzielle Interessen: Angestellte Fach\u00e4rztin (MVZ Endokrinologie Zentrum, Ulm), Diabetologin (DDG), Lipidologin (Deutsche Gesellschaft f\u00fcr Lipidologie [DGFL]), Adiposiologin (Deutsche Adipositas-Gesellschaft [DAG]), DGEM Ern\u00e4hrungsmedizin | Mitgliedschaften: DDG, DGE, DGFL, Deutsche Gesellschaft f\u00fcr Ultraschall in der Medizin (DEGUM).","order":2,"name":"Ethics","label":"Autorinnen und Autoren","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"Die vollst\u00e4ndige Erkl\u00e4rung zum Interessenkonflikt der Wissenschaftlichen Leitung finden Sie am Kurs der zertifizierten Fortbildung auf\n                      \n                      .","order":3,"name":"Ethics","label":"Wissenschaftliche Leitung","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"erkl\u00e4rt, dass f\u00fcr die Publikation dieser CME-Fortbildung keine Sponsorengelder an den Verlag flie\u00dfen.","order":4,"name":"Ethics","label":"Der Verlag","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}}]}}